HHS cancels $500M in mRNA vaccine contracts, shifting focus to vaccine platforms with stronger safety records and greater transparency.
BP's strong Q2 performance driven by robust refining margins and oil trading despite lower oil and gas prices, leading to a dividend increase and ongoing portfolio reviews.
HHS cancels $500M in mRNA vaccine contracts, shifting focus to vaccine platforms with stronger safety records and greater transparency.
BP's strong Q2 performance driven by robust refining margins and oil trading despite lower oil and gas prices, leading to a dividend increase and ongoing portfolio reviews.